GARRICK TONG: Open Payments
NPI 1831361278 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,304 in 66 payments from 13 companies in 2025. Trend: 2023 $1,342 · 2024 $1,312 · 2025 $1,304
Food & beverage: $1,304
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 17 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $222 |
| Otsuka America Pharmaceutical, Inc. | 9 | $160 |
| Alkermes, Inc. | 6 | $121 |
| Neurocrine BioSciences, Inc. | 3 | $106 |
| E.R. Squibb & Sons, L.L.C. | 4 | $99 |
| Teva Pharmaceuticals USA, Inc. | 3 | $79 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
| Lundbeck LLC | 3 | $56 |
| Axsome Therapeutics, Inc. | 1 | $32 |
Products named: Qelbree, CAPLYTA, REXULTI, ARISTADA, INGREZZA, COBENFY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
